Premium
ALUMINUM SULFONATED PHTHALOCYANINE DISTRIBUTION IN RODENT TUMORS OF THE COLON, BRAIN and PANCREAS
Author(s) -
Tralau C. J.,
Barr H.,
Sandeman D. R.,
Barton T.,
Lewin M. R.,
Bown S. G.
Publication year - 1987
Publication title -
photochemistry and photobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 131
eISSN - 1751-1097
pISSN - 0031-8655
DOI - 10.1111/j.1751-1097.1987.tb04847.x
Subject(s) - hematoporphyrin , glioma , hamster , chemistry , cancer , photodynamic therapy , pancreatic cancer , pathology , brain tissue , phthalocyanine , distribution (mathematics) , pancreas , cancer research , medicine , biochemistry , mathematical analysis , mathematics , organic chemistry
The most widely discussed aspect of photodynamic therapy (PDT) is the preferential uptake and retention of sensitisers by malignant tissues. The sensitiser usually used is hematoporphyrin derivative (HPD) but this compound is not an ideal photosensitiser for this purpose and we have therefore studied an aluminum sulfonated phthalocyanine (AlSPc) as a possible alternative. Here we have studied the uptake and retention of this compound in a rat colon cancer, a hamster pancreatic cancer and a mouse glioma, using an alkali extraction technique to estimate tissue AlSPc and comparing the results with those from the corresponding normal tissues. All of the tumors studied reached accumulation peaks at 24‐48 h after intravenous administration of AlSPc compared with peaks at 1‐3 h in the normal tissues. The tumors outside the central nervous system (CNS) reached peak tumor : normal tissue ratios of 2‐3 : 1 and the tumor within the CNS, the malignant glioma, reached a far higher ratio of 28 : 1. These ratios are similar to those reported by others using HPD.